Associated Papers
Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment.
Yu J et al.
Frontiers in Oncology, 2025
41179686 (PubMed )
Supplement: Table3.xls › Mutations_in_36-120d_TISF
Identifying Novel Germline Mutations and Copy Number Variations in Patients With SCLC.
Ul Haq S et al.
Jto Clinical and Research Reports, 2024
39564094 (PubMed )
Supplement: mmc3.xlsx › Sheet1
Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma.
Huang Y et al.
Bmc Endocrine Disorders, 2024
38734621 (PubMed )
Supplement: 12902_2024_1586_MOESM2_ESM.xlsx › Genomic_data
Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways.
Wang X et al.
American Journal of Human Genetics, 2024
Generation and characterization of iPS cell line (SYSUSHi002-A) from PBMCs of an AML patient with TP53 mutation.
Yuan L et al.
Stem Cell Research, 2023
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.
Chevrier S et al.
International Journal of Molecular Medicine, 2022
35244186 (PubMed )
Supplement: Supplementary_Data2.xlsx › Feuil1
Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.
Shen CT et al.
Endocrine, 2019
Select a paper to view details